187 related articles for article (PubMed ID: 35409194)
1. Targeting the DNA Damage Response to Increase Anthracycline-Based Chemotherapy Cytotoxicity in T-Cell Lymphoma.
Magni M; Paolizzi C; Monfrini C; Vella C; Corradini P; Carniti C
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409194
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.
Derenzini E; Agostinelli C; Imbrogno E; Iacobucci I; Casadei B; Brighenti E; Righi S; Fuligni F; Ghelli Luserna Di Rorà A; Ferrari A; Martinelli G; Pileri S; Zinzani PL
Oncotarget; 2015 Mar; 6(9):6553-69. PubMed ID: 25544753
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of DNA damage response pathway using combination of DDR pathway inhibitors and radiation in treatment of acute lymphoblastic leukemia cells.
Katoueezadeh M; Pilehvari N; Fatemi A; Hassanshahi G; Torabizadeh SA
Future Oncol; 2021 Jul; 17(21):2803-2816. PubMed ID: 33960207
[TBL] [Abstract][Full Text] [Related]
5. ATM in DNA repair in cancer.
Jin MH; Oh DY
Pharmacol Ther; 2019 Nov; 203():107391. PubMed ID: 31299316
[TBL] [Abstract][Full Text] [Related]
6. Novel treatments for T-cell lymphoma.
Cheah CY; Oki Y; Fanale MA
Am Soc Clin Oncol Educ Book; 2015; ():e468-78. PubMed ID: 25993211
[TBL] [Abstract][Full Text] [Related]
7. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
[TBL] [Abstract][Full Text] [Related]
8. Anthracycline-containing regimens for treatment of follicular lymphoma in adults.
Itchaki G; Gafter-Gvili A; Lahav M; Vidal L; Raanani P; Shpilberg O; Paul M
Cochrane Database Syst Rev; 2013 Jul; (7):CD008909. PubMed ID: 23832787
[TBL] [Abstract][Full Text] [Related]
9. DNA damage response and repair in pancreatic cancer development and therapy.
Rahnamay Farnood P; Danesh Pazhooh R; Asemi Z; Yousefi B
DNA Repair (Amst); 2021 Jul; 103():103116. PubMed ID: 33882393
[TBL] [Abstract][Full Text] [Related]
10. DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas.
Restelli V; Lupi M; Chilà R; Vagni M; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Damia G; Carrassa L
Mol Cancer Ther; 2019 Jul; 18(7):1255-1264. PubMed ID: 31064869
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors.
Riabinska A; Daheim M; Herter-Sprie GS; Winkler J; Fritz C; Hallek M; Thomas RK; Kreuzer KA; Frenzel LP; Monfared P; Martins-Boucas J; Chen S; Reinhardt HC
Sci Transl Med; 2013 Jun; 5(189):189ra78. PubMed ID: 23761041
[TBL] [Abstract][Full Text] [Related]
12. DNA damage response and hematological malignancy.
Takagi M
Int J Hematol; 2017 Sep; 106(3):345-356. PubMed ID: 28374143
[TBL] [Abstract][Full Text] [Related]
13. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
[TBL] [Abstract][Full Text] [Related]
14. The effect of eIF3a on anthracycline-based chemotherapy resistance by regulating DSB DNA repair.
Chen J; Liu JY; Dong ZZ; Zou T; Wang Z; Shen Y; Zhuo W; Li XP; Xiao D; Liu HT; Chen X; Zhou HH; Liu ZQ; Zhang JT; Yin JY
Biochem Pharmacol; 2021 Aug; 190():114616. PubMed ID: 34022189
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol inhibits Extranodal NK/T cell lymphoma through activation of DNA damage response pathway.
Sui X; Zhang C; Zhou J; Cao S; Xu C; Tang F; Zhi X; Chen B; Wang S; Yin L
J Exp Clin Cancer Res; 2017 Sep; 36(1):133. PubMed ID: 28950914
[TBL] [Abstract][Full Text] [Related]
16. Chlorin e6 mediated photodynamic therapy triggers resistance through ATM-related DNA damage response in lung cancer cells.
Ma QL; Shen MO; Han N; Xu HZ; Peng XC; Li QR; Yu TT; Li LG; Xu X; Liu B; Chen X; Wang MF; Li TF
Photodiagnosis Photodyn Ther; 2022 Mar; 37():102645. PubMed ID: 34823034
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas.
Tse E; Au-Yeung R; Kwong YL
Expert Rev Hematol; 2019 Nov; 12(11):927-935. PubMed ID: 31487202
[No Abstract] [Full Text] [Related]
18. Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds.
Cox MC; Bocci G
Cancer Lett; 2022 Jan; 524():144-150. PubMed ID: 34673128
[TBL] [Abstract][Full Text] [Related]
19. DNA damage response inhibitors: An avenue for TNBC treatment.
Jin J; Tao Z; Cao J; Li T; Hu X
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188521. PubMed ID: 33556453
[TBL] [Abstract][Full Text] [Related]
20. Study of DNA topoisomerase IIa expression in canine lymphomas and its potential role as a marker of sensitivity to anthracycline-based chemotherapy in dogs.
Klimiuk P; Lopuszynski W; Bulak K; Smiech A; Brzana A
Folia Histochem Cytobiol; 2020; 58(1):46-53. PubMed ID: 32176312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
